Adrian Quartel News Today

The phase 2 trial explored the safety and efficacy of KP1077 in reducing daytime sleepiness and sleep inertia.

Zevra's CEO updates shareholders on recent milestones, including the completion of a phase 2 trial for idiopathic hypersomnia.

Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.2.

CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics...

Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate - read this article along with other careers information, tips and advice on BioSpace

$3 million awarded to University of North Carolina (UNC) to support a proposed 180-patient, randomized, placebo-controlled trial in trauma patients ...

Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease - read this article along with other careers information, tips and advice on BioSpace

Relief Therapeutics Holding SA / Key word(s): Regulatory Admission Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in

(2022-08-12 | NDAQ:ACER) Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease

GuruFocus Article or News written by PurpleRose and the topic is about: